Baxter gets rights to Chatham’s hemophilia B gene therapeutic AskBio009
Executive Summary
Chatham Therapeutics LLC (the hemophilia-focused affiliate of large-molecule delivery company Asklepios BioPharmaceutical Inc. (AskBio)) has licensed Baxter BioScience (the recombinant and plasma-based proteins division of Baxter International Inc.’s Baxter Healthcare Corp.) exclusive worldwide rights to its Phase I gene therapeutic AskBio009 for hemophilia B, a single-gene disorder caused by deficient gene coding on the X chromosome of the blood clotting Factor IX.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice